A Phase 1/2 interventional study of monalizumab in Chronic Lymphocytic Leukemia, sponsored by Innate Pharma. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-17.
Sponsored by Innate Pharma · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 138 open to participants now, 252 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.
Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 876th largest by enrollment of the 1,298 interventional ones that give a count, is one of 50 that started in 2015, is one of 172 in phase 1/2, and was the 1,093rd registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →138 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Jennifer Woyach · Sites in United States
Ages 18+
Nurix Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,501 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 657 · Phase 2 724 · Phase 3 120 · Phase 4 6
First in 1986; this study’s year is marked. 50 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 36 across the 1,298 interventional studies, 135 across the 91 observational. Of the 1,167 that completed or were terminated, 470 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,501 have an industry lead sponsor. The 10 most frequent:
Innate Pharma is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Innate Pharma has 1 study filed under Leukemia, Lymphocytic, Chronic, B-Cell — fewer than ten, so there is no comparison to draw.
83 of the studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05624554Phase 3Merck Sharp & Dohme LLCA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | 2027-05-19 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
Add all 83 to your calendar (.ics) → With an account.
Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Combination study of monalizumab (IPH2201) with Ibrutinib in relapsed, refractory or previously untreated Chronic Lymphocytic Leukemia (CLL) patients in 2 parts :
This trial was designated to test the hypothesis that the combination of ibrutinib and IPH2201 will result in a substantial complete response (CR) rate, especially CR without minimal residual disease (MRD), as this has been shown to be associated with long-term clinical benefit.
Up to 45 patients were planned to be enrolled. During the phase 1 part a 3+3 dose escalation design was employed. Four doses were planned to be assessed if the Maximum Tolerated Dose (MTD) was not previously reached: 1, 2, 4 and 10 mg/kg.
During phase 2 part, patients received monalizumab in combination with ibrutinib; monalizumab was given at the dose recommended upon completion of the phase I portion.
The primary objective of the phase 1 was to assess the safety of monalizumab given intravenously as a single agent and in combination with ibrutinib in patients with relapsed, refractory or previously untreated Chronic Lymphocytic Leukemia.
The primary objective of the phase 2 was to evaluate the anti-leukemic activity of the combination of monalizumab and ibrutinib in patients with relapsed, refractory or previously untreated Chronic Lymphocytic Leukemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In phase 1, Monalizumab given at the first dose level of 1 mg/kg.
Drug: monalizumab
In phase 1, Monalizumab given at the second dose level of 2 mg/kg.
Drug: monalizumab
In phase 1, Monalizumab given at the third dose level of 4 mg/kg.
Drug: monalizumab
In phase 2, Monalizumab given at the Recommended Phase 2 Dose (RP2D) of 2 mg/kg, selected by a safety committee.
Drug: monalizumab
During phase 1, patients received monalizumab, IV, at the dose of 1, 2 or 4mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks. During phase 2, patients received monalizumab, IV, at the dose recommended upon completion of phase 1, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of monalizumab (from week 0 to week 6) occured every 2 weeks. From the 5th administration monalizumab was administered every 4 weeks.
Also known as: Anti-NKG2A, IPH2201
Number of Dose Limiting Toxicities
Number of dose-limiting toxicities, measured during the phase 1, dose escalation, part of the study.
Time frame: 8 weeks
Rate of Complete Response (CR)
The rate of complete response (CR) was evaluated using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) grading scale and confirmed by a bone marrow biopsy. Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL), Complete Response (CR) is defined as lymphocytes \<4x109/l, absence of lymphadenopathy, hepatomegaly and splenomegaly at CT scan, no constitutional symptoms, no cytopenia, normocellular bone marrow. Partial Response (PR) is a reduction \> 50% in lymphocytes, lymphadenopathy, spleen or liver, no cytopenia. PD if appearance of any new lesion, or increase in lymphocytes \> 50%, or occurrence of cytopenia attributable to CLL.
Time frame: CR assessed 52 weeks after the beginning of combination treatment
Best Overall Response / Remission Rates
Measure of best overall response at any time during the study. cCR: confirmed complete response/remission; uCR: unconfirmed complete response / remission; PR: partial response/remission; SD: stable disease; PD: progressive disease. Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL), Complete Response (CR) is defined as lymphocytes \<4x109/l, absence of lymphadenopathy, hepatomegaly and splenomegaly at CT scan, no constitutional symptoms, no cytopenia, normocellular bone marrow. Partial Response (PR) is a reduction \> 50% in lymphocytes, lymphadenopathy, spleen or liver, no cytopenia. PD if appearance of any new lesion, or increase in lymphocytes \> 50%, or occurrence of cytopenia attributable to CLL. In order to have a confirmed CR (cCR), the CR must be confirmed by a scan and a bone marrow assessment assessed at least 2 months after the first occurrence of CR. Otherwise it would be an unconfirmed CR (uCR).
Time frame: From beginning of study drug treatment to the end of study (up to 24 months)
Duration of Remission
The duration of remission (DOR) is defined as the time from the date of first evaluation of the remission (cCR, uCR or PR) to the first documentation of progressive disease, relapsed disease or death. In case an assessment of progressive / relapsed disease or death does not exist, the DOR was censored at the time of the last disease assessment date. The DOR was calculated only for the patients with a remission that was assessed at 52 weeks.
Time frame: Up to 24 months
Progression Free Survival
The Progression Free Survival (PFS) is defined as the time from first dose administration until the occurrence of progressive disease, relapsed disease or death from any cause. Patients without an event at the time of the analyse were censored at his or her last disease assessment date. Patients with no post-Baseline assessment were censored at the day of the first dose administration.
Time frame: Up to 24 months
Overall Survival
The overall survival (OS) is defined as the time from first dose administration until death from any cause. Alive patients were censored at the most recent date they were known to be alive. Subjects with no assessment post-Baseline were censored at the day of the first dose administration.
Time frame: Up to 24 months.
It was anticipated that up to 24 patients (3 to 6 patients; 4 dose levels) would be enrolled in Phase 1 part of the study and up to 24 patients in the Phase 2 part with a total of up to 45 patients in the trial. A total of 22 patients were actually enrolled in the study: 13 patients in the Phase 1 part and 9 patients in the Phase 2 part.
| Milestone | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg |
|---|---|---|---|---|
| Started | 3 | 6 | 4 | 9 |
| Completed | 2 | 1 | 0 | 0 |
| Not completed | 1 | 5 | 4 | 9 |
| Withdrew: Adverse event | 1 | 0 | 2 | 1 |
| Withdrew: Disease progression | 0 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 1 | 2 | 8 |
Number of dose-limiting toxicities, measured during the phase 1, dose escalation, part of the study.
| Dose Limiting Toxicy | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg |
|---|---|---|---|
| Number of Dose Limiting Toxicities | 0 | 1 | 2 |
The rate of complete response (CR) was evaluated using the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) grading scale and confirmed by a bone marrow biopsy. Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL), Complete Response (CR) is defined as lymphocytes \<4x109/l, absence of lymphadenopathy, hepatomegaly and splenomegaly at CT scan, no constitutional symptoms, no cytopenia, normocellular bone marrow. Partial Response (PR) is a reduction \> 50% in lymphocytes, lymphadenopathy, spleen or liver, no cytopenia. PD if appearance of any new lesion, or increase in lymphocytes \> 50%, or occurrence of cytopenia attributable to CLL.
| Participants | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg |
|---|---|---|---|---|
| Rate of Complete Response (CR) | 1 | 1 | 0 | 0 |
Measure of best overall response at any time during the study. cCR: confirmed complete response/remission; uCR: unconfirmed complete response / remission; PR: partial response/remission; SD: stable disease; PD: progressive disease. Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL), Complete Response (CR) is defined as lymphocytes \<4x109/l, absence of lymphadenopathy, hepatomegaly and splenomegaly at CT scan, no constitutional symptoms, no cytopenia, normocellular bone marrow. Partial Response (PR) is a reduction \> 50% in lymphocytes, lymphadenopathy, spleen or liver, no cytopenia. PD if appearance of any new lesion, or increase in lymphocytes \> 50%, or occurrence of cytopenia attributable to CLL. In order to have a confirmed CR (cCR), the CR must be confirmed by a scan and a bone marrow assessment assessed at least 2 months after the first occurrence of CR. Otherwise it would be an unconfirmed CR (uCR).
| Participants | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg |
|---|---|---|---|---|
| cCR | 1 | 1 | 0 | 0 |
| uCR | 0 | 1 | 0 | 0 |
| PR | 2 | 3 | 2 | 6 |
| SD | 0 | 1 | 1 | 3 |
| PD | 0 | 0 | 0 | 0 |
The duration of remission (DOR) is defined as the time from the date of first evaluation of the remission (cCR, uCR or PR) to the first documentation of progressive disease, relapsed disease or death. In case an assessment of progressive / relapsed disease or death does not exist, the DOR was censored at the time of the last disease assessment date. The DOR was calculated only for the patients with a remission that was assessed at 52 weeks.
| Month | Efficacy Population |
|---|---|
| Duration of Remission | NA (NA to NA) |
The Progression Free Survival (PFS) is defined as the time from first dose administration until the occurrence of progressive disease, relapsed disease or death from any cause. Patients without an event at the time of the analyse were censored at his or her last disease assessment date. Patients with no post-Baseline assessment were censored at the day of the first dose administration.
| Month | ITT / Safety Population |
|---|---|
| Progression Free Survival | NA (NA to NA) |
The overall survival (OS) is defined as the time from first dose administration until death from any cause. Alive patients were censored at the most recent date they were known to be alive. Subjects with no assessment post-Baseline were censored at the day of the first dose administration.
| Month | All ITT / Safety Population |
|---|---|
| Overall Survival | NA (NA to NA) |
Collected over The occurrences of Adverse Events were recorded from the time of signed informed consent until the end of the patient's participation to the trial (up to 24 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 mg/kg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| 2 mg/kg | 0/15 (0%) | 5/15 (33.3%) | 15/15 (100%) |
| 4 mg/kg | 0/4 (0%) | 3/4 (75%) | 4/4 (100%) |
| Event | 1 mg/kg | 2 mg/kg | 4 mg/kg |
|---|---|---|---|
| Supraventricular tachycardiaCardiac disorders | 1/3 | 0/15 | 0/4 |
| UrosepsisInfections and infestations | 1/3 | 0/15 | 0/4 |
| Myelodysplastic syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/3 | 0/15 | 0/4 |
| Large intestinal haemorrhageGastrointestinal disorders | 0/3 | 0/15 | 1/4 |
| PyrexiaGeneral disorders | 0/3 | 0/15 | 1/4 |
| Amylase increasedInvestigations | 0/3 | 0/15 | 1/4 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/3 | 0/15 | 1/4 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/15 | 1/4 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 0/3 | 1/15 | 0/4 |
| SinusitisInfections and infestations | 0/3 | 1/15 | 0/4 |
| Event | 1 mg/kg | 2 mg/kg | 4 mg/kg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/3 | 9/15 | 4/4 |
| ContusionInjury, poisoning and procedural complications | 3/3 | 8/15 | 0/4 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 5/15 | 0/4 |
| Back painMusculoskeletal and connective tissue disorders | 2/3 | 1/15 | 0/4 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/3 | 7/15 | 1/4 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/3 | 5/15 | 0/4 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/3 | 2/15 | 2/4 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/3 | 4/15 | 0/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/3 | 8/15 | 2/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/3 | 8/15 | 2/4 |
| Age, Continuous(years) | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg | Total |
|---|---|---|---|---|---|
| Mean | 59.3 ± 11.15 | 65.8 ± 7.14 | 69.5 ± 10.08 | 69.4 ± 6.33 | 67.1 ± 8.14 |
| Sex: Female, Male(Participants) | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg | Total |
|---|---|---|---|---|---|
| Female | 0 | 3 | 3 | 2 | 8 |
| Male | 3 | 3 | 1 | 7 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 6 | 4 | 9 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 1 |
| White | 3 | 6 | 4 | 7 | 20 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg | Total |
|---|---|---|---|---|---|
| United States | 3 | 6 | 4 | 9 | 22 |
| ECOG Performance Status(Participants) | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg | Total |
|---|---|---|---|---|---|
| ECOG 0 | 3 | 2 | 0 | 7 | 12 |
| ECOG 1 | 0 | 4 | 4 | 2 | 10 |
| RAI Stage(Participants) | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg | Total |
|---|---|---|---|---|---|
| Stage I | 0 | 0 | 0 | 3 | 3 |
| Stage II | 2 | 1 | 0 | 0 | 3 |
| Stage III | 0 | 1 | 1 | 0 | 2 |
| Stage IV | 1 | 4 | 3 | 6 | 14 |
| Disease Status at Screening(Participants) | Phase 1 Level 1 - 1 mg/kg | Phase 1 Level 2 - 2 mg/kg | Phase 1 Level 3 - 4 mg/kg | Phase 2 RP2D - 2 mg/kg | Total |
|---|---|---|---|---|---|
| Previously Untreated CLL | 0 | 1 | 0 | 6 | 7 |
| Refractory CLL | 0 | 1 | 1 | 0 | 2 |
| Relapse CLL | 3 | 4 | 3 | 3 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Oct 2018, 35 months.
Results were first posted in Dec 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Monalizumab
Leukemia, Lymphocytic, Chronic, B-Cell →
Innate Pharma